Follow-up study of extra stem cell doses for Alzheimer's
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial is a follow-up for people who already received a single dose of RB-ADSC (a stem cell treatment) in an earlier study. It tests whether more doses, given through a small brain injection, are safe and might help with Alzheimer's.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in the earlier RB-ADSC-02 study and finished it completely.
- You must have a family member or caregiver who can watch for side effects and agree to the study's caregiver rules.
- You must not have had a serious side effect related to the treatment in the earlier study.
- You must be willing to give written permission (or have a legal representative do it) to join this extension study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new stem cell treatment (called RB-ADSCs) that is injected into the fluid around your brain. It aims to see if these cells can help slow down memory loss and thinking problems in people with mild to moderate Alzheimer's disease.
This Phase 1 study tests whether injecting your own (autologous) activated fat-derived stem cells into the brain is safe and potentially helpful for mild to moderate Alzheimer’s disease. The goal is to see how the treatment affects the brain and symptoms, using cells made from your own donated fat tissue.
This trial tests whether stem cells from donated fat tissue can help people with mild to moderate Alzheimer's disease. It combines infusions of these cells with standard care, and includes brain scans and memory tests to see if the treatment is safe and effective.
This trial continues treatment for people who finished the earlier SNK01-AD01 study. It tests a personalized cell therapy (SNK01) to see if ongoing treatment is safe and helpful for Alzheimer's disease.
This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.